Parkinson s Disease Therapeutics

Parkinson   s Disease Therapeutics
Author: Magisetty Obulesu
Publsiher: Academic Press
Total Pages: 146
Release: 2020-01-30
ISBN 10: 0128198834
ISBN 13: 9780128198834
Language: EN, FR, DE, ES & NL

Parkinson s Disease Therapeutics Book Review:

Parkinson’s Disease Therapeutics: Emphasis on Nanotechnological Advances presents the latest information on the second most common neurodegenerative disorder in the elderly. Despite remarkable progress in various PD therapeutics, such as microRNAs and brain drug delivery systems, a few limitations impede their success. This book sheds light on the pros and cons of recently developed novel therapeutics. Very few books have highlighted the protective efficacy of natural products, antioxidants, and biomaterial design for other diseases. Emphasizes novel therapeutics for Parkinson’s disease, including nanotechnology, natural products and antioxidants Discusses the pros and cons of recently developed therapy options for Parkinson's Focuses on the efficacy of nanotechnology in overcoming the blood-brain barrier and biomaterial design

Parkinson s Disease Therapeutics

Parkinson s Disease Therapeutics
Author: Magisetty Obulesu
Publsiher: Academic Press
Total Pages: 200
Release: 2020-01-24
ISBN 10: 9780128198827
ISBN 13: 0128198826
Language: EN, FR, DE, ES & NL

Parkinson s Disease Therapeutics Book Review:

Parkinson's Disease is the second most common neurodegenerative disorder in the elderly. Vital pathological events include a decline in nigrostriatal neurons and deterioration of the neurotransmitter dopamine. Since amyloid fibrils are the key end products of several proteins implicated in neurodegenerative diseases, multiple studies emphasize their diagnosis as the mainstay of current research. Despite remarkable progress in various PD therapeutics such as microRNAs and brain drug delivery systems, a few limitations impede their success. In addition, nanotechnological therapeutics avenues employed to date for brain diseases have not been as effective strategies as they are for other diseases. This book will shed light on the pros and cons of recently developed novel therapeutics. Very few books have highlighted the protective efficacy of natural products, antioxidants, and biomaterial design for other diseases. However, the efficacy of nanotechnology in overcoming the bioavailability issues associated with drugs, natural products and antioxidants, and their use in Parkinson's Disease therapy has not yet been summarized in the form of a book. Numerous unresolved major drawbacks of the existing therapeutic strategies and Nanotechnology in Parkinson's Disease treatment will be highlighted and possible future perspectives to overcome current challenges will be emphasized. Emphasizes novel therapeutics for Parkinson's disease including nanotechnology, natural products, and antioxidants Discusses the pros and cons of multiple recently developed therapy options for Parkinson's Focuses on the efficacy of nanotechnology in overcoming the blood-brain barrier and biomaterial design

Therapeutics of Parkinson s Disease and Other Movement Disorders

Therapeutics of Parkinson s Disease and Other Movement Disorders
Author: Mark Hallett,Werner Poewe
Publsiher: John Wiley & Sons
Total Pages: 520
Release: 2008-10-13
ISBN 10: 047071400X
ISBN 13: 9780470714003
Language: EN, FR, DE, ES & NL

Therapeutics of Parkinson s Disease and Other Movement Disorders Book Review:

Provides a comprehensive update on therapies for Parkinson’s disease and other movement disorders Describes the basic mechanisms of neurodegeneration, pharmacologic interventions for motor and non-motor symptoms, and surgical management Features summary tables and algorithms that serve as a quick reference guide for practical treatment decisions The expert guidance of recognised authorities will enable readers of this book to plan their patients’ care with greater confidence

Novel Therapeutic Approaches to the Treatment of Parkinson s Disease

Novel Therapeutic Approaches to the Treatment of Parkinson   s Disease
Author: Corey R. Hopkins
Publsiher: Springer
Total Pages: 151
Release: 2016-07-25
ISBN 10: 9783319399249
ISBN 13: 3319399241
Language: EN, FR, DE, ES & NL

Novel Therapeutic Approaches to the Treatment of Parkinson s Disease Book Review:

Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors.

Improving Therapeutics for Parkinson s Disease

Improving Therapeutics for Parkinson s Disease
Author: Jennifer A. O'Malley
Publsiher: Unknown
Total Pages: 394
Release: 2009
ISBN 10: 1928374650XXX
ISBN 13: OCLC:609415013
Language: EN, FR, DE, ES & NL

Improving Therapeutics for Parkinson s Disease Book Review:

The following results are from studies designed with the overall goal of elucidating means for improving therapeutics for Parkinson's disease. There is still much to be understood regarding the cellular and molecular mechanisms underlying the development of side effects to therapies for Parkinson's disease such as levodopa-induced dyskinesias. Additionally, therapeutic intervention is further complicated when one considers the role of the functionally waning host environment, especially in the context of its responsivity to therapeutic agents. The work in this thesis was designed to focus on two aspects of Parkinson's disease therapeutics, (1) improving graft efficacy by contributing additional information on how the host environment in regards to age impacts graft function in Parkinson's disease, and (2) determining whether specific morphological changes of the nigral target neurons within the striatum impact development or severity of levodopa-induced dyskinesias. The first study demonstrates that while the aging striatum can, under specific conditions, support the survival of large numbers of grafted embryonic dopamine neurons, there is limited functional benefit even with robust cell survival. This realization is an important contribution to the field as it newly suggests the aged striatum is capable of supporting grafted dopamine neurons, but the limited efficacy of these grafts demonstrates the importance of the intricate balance between grafted cells and the aged host environment. The second study demonstrate that maintaining appropriate synaptic contacts that are presumably maintained when striatal medium spiny neuron cytoarchitecture is preserved, resulting in reduced drug-induced side-effects in parkinsonian rats. Future experiments are needed to explore the specific requirements of the aging striatum for functional recovery and how to implement synaptic stability of medium spiny neurons in clinical practice to potentially decrease side-effects of dopamine replacement pharmacotherapy.

Parkinson s Disease

Parkinson s Disease
Author: Sarat Chandra Yenisetti
Publsiher: BoD – Books on Demand
Total Pages: 126
Release: 2018-05-30
ISBN 10: 1789231523
ISBN 13: 9781789231526
Language: EN, FR, DE, ES & NL

Parkinson s Disease Book Review:

Parkinson's disease (PD) is the second most common neurodegenerative disorder results due to loss of dopamine producing brain cells. Knowledge relating to PD condition has been known since 5000BC, however no effective therapeutic strategies are available till today. Therefore it is important for neurobiologists to work further by taking advantage of modern scientific methods and develop appropriate therapeutic strategies. Efforts in this direction are worthy as they will reduce the burden of PD among elderly, who are already burdened with age related systemic degenerative processes. This book is a humble effort in that progressive direction. It has chapters covering multiple aspects relating to etiology, pathophysiology of PD, available and futuristic therapeutics strategies. Therefore it will be of interest to common man, biomedical researchers and clinicians. This is one small step in a direction "to reduce the burden of neurological disease."

Parkinson s Disease Current and Future Therapeutics and Clinical Trials

Parkinson s Disease  Current and Future Therapeutics and Clinical Trials
Author: Nestor Galvez-Jimenez,Hubert H. Fernandez,Alberto J. Espay,Susan H. Fox
Publsiher: Cambridge University Press
Total Pages: 384
Release: 2016-03-31
ISBN 10: 1107053862
ISBN 13: 9781107053861
Language: EN, FR, DE, ES & NL

Parkinson s Disease Current and Future Therapeutics and Clinical Trials Book Review:

This book emphasizes treatment options for Parkinson's disease, providing the necessary clinical and scientific basis for the foundations of solid therapeutics.

Towards New Therapies for Parkinson s Disease

Towards New Therapies for Parkinson s Disease
Author: David Finkelstein
Publsiher: BoD – Books on Demand
Total Pages: 410
Release: 2011-11-02
ISBN 10: 9533074639
ISBN 13: 9789533074634
Language: EN, FR, DE, ES & NL

Towards New Therapies for Parkinson s Disease Book Review:

Parkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies.

The Impact of Price Controls on the Future Development of Parkinson s Disease Therapeutics

The Impact of Price Controls on the Future Development of Parkinson s Disease Therapeutics
Author: Peter White Latham
Publsiher: Unknown
Total Pages: 100
Release: 1994
ISBN 10: 1928374650XXX
ISBN 13: OCLC:31537682
Language: EN, FR, DE, ES & NL

The Impact of Price Controls on the Future Development of Parkinson s Disease Therapeutics Book Review:

Encyclopedia of Parkinson s Disease

Encyclopedia of Parkinson s Disease
Author: Kate White
Publsiher: Hayle Medical
Total Pages: 216
Release: 2015-02-17
ISBN 10: 9781632411945
ISBN 13: 1632411946
Language: EN, FR, DE, ES & NL

Encyclopedia of Parkinson s Disease Book Review:

Various therapeutic modalities and treatments of Parkinson's disease (PD) have been described in this book. This disease is caused mainly due to the death of dopaminergic neurons in the substantia nigra. Recent PD medications treat symptoms; though none decrease the rate of dopaminergic neuron degeneration. The primary problem in development of neuroprotective therapies is a restricted comprehension of the crucial molecular mechanisms that incite neurodegeneration. The discovery of PD genes has led to the hypothesis that dysfunction of the ubiquitin-proteasome pathway and misfolding of proteins are both critical to pathogenesis of the disease. Oxidative stress and mitochondrial dysfunction, earlier labeled as responsible in the neurodegeneration of this disease, may also act in part by causing the collection of misfolded proteins, along with the production of other harmful events in dopaminergic neurons. PD models based on the manipulation of PD genes should prove crucial in explaining significant characteristics of the disease, like selective vulnerability of substantia nigra dopaminergic neurons to the degenerative process. Some important topics include theoretical model for PD, PD in drosophila, animal models of PD, etc.

Peripheral Immunity in Parkinson s Disease Emerging Role and Novel Target for Therapeutics

Peripheral Immunity in Parkinson s Disease  Emerging Role and Novel Target for Therapeutics
Author: Cristoforo Comi,Marco Cosentino,Rodrigo Pacheco
Publsiher: Frontiers Media SA
Total Pages: 135
Release: 2019-12-23
ISBN 10: 2889632857
ISBN 13: 9782889632855
Language: EN, FR, DE, ES & NL

Peripheral Immunity in Parkinson s Disease Emerging Role and Novel Target for Therapeutics Book Review:

Deep Brain Stimulation for Parkinson s Disease

Deep Brain Stimulation for Parkinson s Disease
Author: Gordon H. Baltuch,Matthew B. Stern
Publsiher: CRC Press
Total Pages: 372
Release: 2007-03-19
ISBN 10: 1420019759
ISBN 13: 9781420019759
Language: EN, FR, DE, ES & NL

Deep Brain Stimulation for Parkinson s Disease Book Review:

Considered the largest breakthrough in the treatment of Parkinson's disease in the past 40 years, Deep Brain Stimulation (DBS) is a pioneering procedure of neurology and functional neurosurgery, forging enormous change and growth within the field. The first comprehensive text devoted to this surgical therapy, Deep Brain Stimulation for Parkinson's

Parkinson s Disease

Parkinson s Disease
Author: Dr. Stewart A. Factor, DO,Dr. William Weiner, MD
Publsiher: Demos Medical Publishing
Total Pages: 1024
Release: 2007-12-15
ISBN 10: 9781934559871
ISBN 13: 1934559873
Language: EN, FR, DE, ES & NL

Parkinson s Disease Book Review:

Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. Still the only major text on the subject, the completely revised and updated second edition of Parkinson's Disease: Diagnosis and Clinical Management comes at a time when specialists have made important advances in our understanding of the etiology, pathogenesis, investigation, and management of Parkinson's disease. The book includes 23 completely new chapters, and has updated information on: Genetics Pathology Biomarkers Pathogenesis Impulse control disorders in Parkinson's disease Updated outcome measures Complementary and alternative medicine for the treatment of Parkinson's disease Together the chapters form a comprehensive review of the many issues facing PD physicians today. Lucid and easily readable from beginning to end, each chapter may also stand on its own as a scholarly review of the individual subject. Each one is concisely written and heavily referenced for this purpose. The second edition of Parkinson's Disease: Diagnosis and Clinical Management provides a state-of-the-art review of where we've been, where we are now, and where we are going in treating this disease.

Parkinson s Disease

Parkinson   s Disease
Author: F. Messiha
Publsiher: Springer
Total Pages: 316
Release: 2012-07-12
ISBN 10: 9781468425130
ISBN 13: 1468425137
Language: EN, FR, DE, ES & NL

Parkinson s Disease Book Review:

These Proceedings are the outcome of the First Tarbox Parkinson's Disease Symposium held October 14-16, 1976, at the South Park Inn in Lubbock, Texas. The Symposium was sponsored by the Department of Pharmacology and Therapeutics and the Tarbox Parkinson's Disease In stitute of the Texas Tech University School of Medicine at Lubbock. The Tarbox Parkinson's Disease Institute was established in 1973 with funds appropriated by the State of Texas and is dedicated to re search, patient care, and educational activities related to Parkinson's disease. The Institute is named after Mr. Elmer L. Tarbox, who recently served the Lubbock area as a Representative to the Texas Legislature, and is himself a parkinsonian patient. Mr. and Mrs. Tarbox attended the Symposium as honored guests. The First Tarbox Parkinson's Disease Symposium was devoted to both basic and clinical aspects of Parkinson's disease, with an emphasis on discussion of drug therapy. This discussion focused not only on readily available drugs such as levodopa, but also on new investigational drugs such as bromocriptine. Thanks are especially due to Thelma Saunders and the office staff of the Department of Pharmacology and Therapeutics, Texas Tech Univer sity School of Medicine, for their excellent service in producing camera-ready copy for the Publisher. Thanks are also due to Fathy S. Messiha, Program Chairman, to the other committee members, and to the staff of the Office of Continuing Education and Faculty Development. The Symposium could not have succeeded without their help.

A History of Therapeutics in Parkinson s Disease

A History of Therapeutics in Parkinson s Disease
Author: Anonim
Publsiher: Unknown
Total Pages: 178
Release: 1994
ISBN 10: 1928374650XXX
ISBN 13: OCLC:927992106
Language: EN, FR, DE, ES & NL

A History of Therapeutics in Parkinson s Disease Book Review:

Recent Advances in Parkinson s Disease Basic research

Recent Advances in Parkinson s Disease  Basic research
Author: Anders Björklund,M. Angela Cenci
Publsiher: Elsevier
Total Pages: 320
Release: 2010
ISBN 10: 0444536140
ISBN 13: 9780444536143
Language: EN, FR, DE, ES & NL

Recent Advances in Parkinson s Disease Basic research Book Review:

Neuroendocrinology is a discipline which originated about 50 years ago as a branch of Endocrinology and that is now strictly linked to neuroscience. Volumes 181 and 182 of Progress in Brain Research provide a rapid view of the major points presently discussed at biological and clinical levels. The chapters have been written by top scientists who are directly involved in basic or clinical research and who use the most sophisticated biotechnological techniques. The volumes cover of the role of genetics in many endocrine-related events, like neuroendocrinological diseases and endocrine depenedent cancers (prostate, breast, etc,). Interesting information is also provided on possibile treatments of neurodegenerative brain diseases (e.g., Alzheimer and similar syndromes). . The best researchers in the field provide their conclusions in the context of the latest experimental results . Chapters are extensively referenced to provide readers with a comprehensive list of resources on the topics covered . Of great value for researchers and experts, but also for students as a background reference

Parkinson s Disease

Parkinson s Disease
Author: Richard Nass,Serge Przedborski
Publsiher: Elsevier
Total Pages: 686
Release: 2011-04-28
ISBN 10: 9780080559582
ISBN 13: 0080559581
Language: EN, FR, DE, ES & NL

Parkinson s Disease Book Review:

Parkinson’s disease is the second most prevalent neurodegenerative disease and is characterized by the irreversible loss of dopamine neurons. Despite its high prevalence in society and many decades of research, the origin of the pathogenesis and the molecular determinants involved in the disorder has remained elusive. Confounding this issue is the lack of experimental models that completely recapitulate the disease state. The identification of a number of genes thought to play a role in the cell death, and development of both toxin and genetic models to explore the function of the genes both in unaffected and diseased cells are now providing new insights into the molecular basis of the neurodegeneration, as well as therapeutic approaches. In this reference, we will describe the advances and the advantages that various invertebrates, cell culture, rodents, and mammals provide in the identification of the molecular components and mechanisms involved in the cell death, and outline the opportunities that these systems provide in drug discovery. Comprehensive and critical assessment of the utility of various model systems to identify the molecular components and pathways involved in Parkinson’s disease Describes the power of toxin and genetic models to identify novel therapeutic targets and compounds that can be used in PD Current overviews of current status of PD research and discovery from bench-to-bedside Provides novel insights and views on where the future of PD research may lead Provides a powerful teaching tool and template to explore the utility of model systems to identify molecular pathways, molecular targets, and therapeutics that are applicable to a variety of neurological diseases

Etiology of Parkinson s Disease

Etiology of Parkinson s Disease
Author: Jonas H. Ellenberg,William C. Koller,James William Langston
Publsiher: CRC Press
Total Pages: 600
Release: 1995-03-01
ISBN 10: 9780824788230
ISBN 13: 0824788230
Language: EN, FR, DE, ES & NL

Etiology of Parkinson s Disease Book Review:

This comprehensive reference provides a detailed overview of current concepts regarding the cause of Parkinson's disease-emphasizing the issues involved in the design, implementation, and analysis of epidemiological studies of parkinsonism.

Something Old Something New

Something Old Something New
Author: Carol A. Lazzara
Publsiher: Unknown
Total Pages: 65
Release: 2014
ISBN 10: 1928374650XXX
ISBN 13: OCLC:1109726538
Language: EN, FR, DE, ES & NL

Something Old Something New Book Review:

Levodopa Induced Dyskinesia in Parkinson s Disease

Levodopa Induced Dyskinesia in Parkinson s Disease
Author: Susan H. Fox,Jonathan M. Brotchie
Publsiher: Springer
Total Pages: 368
Release: 2014-10-08
ISBN 10: 1447165039
ISBN 13: 9781447165033
Language: EN, FR, DE, ES & NL

Levodopa Induced Dyskinesia in Parkinson s Disease Book Review:

This book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from ‘bench to bedside’. Initial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; on going RCTs in LID and evidence-based medicine reviews of treatment options. Levodopa-Induced Dyskinesia in Parkinson’s Disease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees and graduate and post-graduate students.